Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.57 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17438485 | 0.98 | TDP1 (0.55) | TDP1SIRT3MKNK1MKNK2KDM4E | |
| SCHEMBL17438491 | 0.98 | TDP1 (0.55) | TDP1SIRT3MKNK1MKNK2KDM4E | |
| SCHEMBL1369445 | 0.83 | SIRT3 (0.62) | TDP1SIRT3MKNK1MKNK2KDM4E | |
| SCHEMBL28255112 | 0.82 | KDM4C (0.47) | TDP1SIRT3KDM4EALDH1A1MAPT | |
| SCHEMBL1330970 | 0.82 | TDP1 (0.67) | TDP1SIRT3MKNK1MKNK2KDM4E | |
| SCHEMBL1687197 | 0.82 | TDP1 (0.67) | TDP1SIRT3MKNK1MKNK2KDM4E | |
| Hydrochloric Acid SCHEMBL4598141 | 0.81 | SIRT3 (0.60) | TDP1SIRT3MKNK1MKNK2KDM4E | |
| SCHEMBL29822292 | 0.80 | KDM4C (0.61) | TDP1KDM4EALDH1A1MAPTTSHR | |
| SCHEMBL2562774 | 0.80 | KDM4C (0.61) | TDP1KDM4EALDH1A1MAPTTSHR | |
| SCHEMBL5700307 | 0.78 | TDP1 (0.57) | TDP1SIRT3MKNK1MKNK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116267014-A | Cyclic deuterated gaboxadol and its use for treating psychotic disorders | CERTEGO治疗公司 | 2023-06-20 | — | — | CN | claimed |
| EP-2978427-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR INT AG (CH) | 2018-08-08 | — | — | EP | claimed |
| CN-116267014-A | Cyclic deuterated gaboxadol and its use for treating psychotic disorders | CERTEGO治疗公司 | 2023-06-20 | — | — | CN | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| CN-115244037-A | Substituted triazinones as thyroid hormone receptor agonists | 上海诚益生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-110734429-B | Usnea nicotinamide compound and preparation method and application thereof | 昆明医科大学 | 2022-05-03 | — | — | CN | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| EP-3704103-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | University of Miami (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-2978427-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR INT AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| US-20060094724-A1 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1723210-A | Fused furan compound | TANABE SEIYAKU CO (JP) | 2006-01-18 | — | — | CN | disclosed |
| EP-1582521-A1 | FUSED FURAN COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| CN-1492874-A | Macrolide antibiotics | — | 2004-04-28 | — | — | CN | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| WO-1990003379-A1 | PHOTOCHROMIC SUBSTANCES | OPTISCHE WERKE G. RODENSTOCK (DE) | 1990-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | TDP1 3408/4885SIRT3 680/4885MKNK1 2527/4885 |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | TDP1 1130/4885SIRT3 1871/4885MKNK1 1807/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | TDP1 1714/4885SIRT3 3184/4885MKNK1 3068/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | TDP1 2058/4885SIRT3 3463/4885MKNK1 3230/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | TDP1 1739/4885SIRT3 3116/4885MKNK1 3058/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | TDP1 2834/4885SIRT3 549/4885MKNK1 2117/4885 |
| US-20060094724-A1 | Fused furan compound | F2, F12, F11 | TDP1 4423/4885SIRT3 1544/4885MKNK1 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.